AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	5489	1398396-25-2

Description:

Molecule	Description
Molfile Synonyms: diclofenac etalhyaluronate sodium joycle SI-613 ONO 5704 ONO-5704/SI-613	Diclofenac etalhyaluronate is a 130,000 kDa compound in which the diclofenac molecule is attached via a 2-aminoethanol linker to the glucuronic acid moiety of the hyaluronic acid. Diclofenac is released through hydrolytic cleavage of the ester linkage and it inhibits the synthesis of prostaglandin E2. Molecular weight: Formula: H2O(C30H35Cl2N3O12)a(C14H20NO11)b CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

diclofenac etalhyaluronate sodium
joycle
SI-613
ONO 5704
ONO-5704/SI-613

Diclofenac etalhyaluronate is a 130,000 kDa compound in which the diclofenac molecule is attached via a 2-aminoethanol linker to the glucuronic acid moiety of the hyaluronic acid. Diclofenac is released through hydrolytic cleavage of the ester linkage and it inhibits the synthesis of prostaglandin E2.

Molecular weight:
Formula: H2O(C30H35Cl2N3O12)a(C14H20NO11)b
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
March 23, 2021	PMDA	Seikagaku Corporation

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Osteoarthritis of hip	indication	239872002
Osteoarthritis of knee	indication	239873007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Prostaglandin E2 receptor EP2 subtype	GPCR	P43116	PE2R2_HUMAN					UNKNOWN	DRUG LABEL

External reference:

ID	Source
CHEBI:756738	CHEBI
CHEMBL4297232	ChEMBL_ID
D11020	KEGG_DRUG
C5420904	UMLSCUI
CHEMBL4297231	ChEMBL_ID
86278363	PUBCHEM_CID
LG1II3835L	UNII
C000656259	MESH_SUPPLEMENTAL_RECORD_UI
LG1II3835L	INXIGHT DRUGS

Pharmaceutical products:

None

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

diclofenac etalhyaluronate sodium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: